TABLE 5.
Commonly prescribed antihypertensive CPM combination and guideline concordance.
| Internet hospitals | Guidelines | ||||
|---|---|---|---|---|---|
| Prescribed CPM combination | Support (%) | Confidence (%) | Lift | 2021 CPM guideline | 2019 hypertension expert consensus |
| CPM combined with WM | |||||
| JQNLQ + A | 17.15 | 4.64 | 0.81 | ✕ | ✕ |
| JQNLQ + B | 17.15 | 2.88 | 0.84 | ✕ | ✕ |
| JQNLQ + C | 17.15 | 2.6 | 0.88 | ✕ | ✕ |
| ZJJYT+ A | 14.08 | 5.07 | 0.89 | ✕ | ✕ |
| ZJJYT + B | 14.08 | 3.59 | 1.05 | ✕ | ✕ |
| ZJJYT + D | 14.08 | 2.51 | 1.26 | ✕ | ✕ |
| ZJJYT + C | 14.08 | 2.17 | 0.73 | ✕ | ✕ |
| QLDXT + A | 12.06 | 3.64 | 0.64 | ✓ | ✕ |
| QLDXT+ C | 12.06 | 2.77 | 0.94 | ✓ | ✕ |
| QLDXT + B | 12.06 | 2.48 | 0.73 | ✓ | ✕ |
| CPM combined with CPM | |||||
| JQNLQ + QLDXT | 8.65 | 0.44 | 0.06 | ✕ | ✕ |
| JQNLQ + NHJYT | 8.65 | 0.42 | 0.14 | ✕ | ✕ |
| JQNLQ + QNJYT | 8.65 | 0.32 | 0.06 | ✕ | ✕ |
| QLDXT + QNJYT | 7.23 | 0.29 | 0.05 | ✕ | ✕ |
| QNJYT + NHJYT | 5.33 | 0.34 | 0.11 | ✕ | ✕ |
| QNJYT + DZPYT | 5.33 | 0.24 | 0.26 | ✕ | ✕ |
| NHJYT + QLDXT | 2.99 | 0.4 | 0.06 | ✕ | ✕ |
| NHJYT + LBMJYT | 2.99 | 0.23 | 0.13 | ✕ | ✕ |
| LBMJYT + QNJYT | 1.8 | 0.5 | 0.09 | ✕ | ✕ |
| LBMJYT + QLDXT | 1.8 | 0.39 | 0.05 | ✕ | ✕ |
Note: JQNLQ, jiuqiang naoliqing; ZJJYT, zhenju jiangya tablet; QLDXT, Qiangli Dingxuan tablet/capsule; NHJYT, Niuhuang Jiangya tablet/pill; QNJYT, qingnao jiangya tablet; DZPYT, duzhong pinya tablet; LBMJYT, luobuma jiangya tablet; A, nifedipine; B, metoprolol tartrate; C, candesartan cilexetil; D, amlodipine besilate; ✓: Concordance with guideline recommendations; ✕: Discordant with guideline recommendations.